Next quarter’s earnings estimate for GHD is -EUR 0.16 with a range of -EUR 0.16 to -EUR 0.16. The previous quarter’s EPS was -EUR 0.31. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.
Next quarter’s earnings estimate for GHD is -EUR 0.16 with a range of -EUR 0.16 to -EUR 0.16. The previous quarter’s EPS was -EUR 0.31. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.
Next quarter’s sales forecast for GHD is EUR 0 with a range of ― to ―. The previous quarter’s sales results were EUR 0. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.
Next quarter’s sales forecast for GHD is EUR 0 with a range of ― to ―. The previous quarter’s sales results were EUR 0. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.
GHD Stock Forecast FAQ
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Brainstorm Cell Therapeutics a Buy, Sell or Hold?
Brainstorm Cell Therapeutics has a consensus rating of Hold, which is based on 0 buy ratings, 1 hold ratings and 0 sell ratings.
What do analysts say about Brainstorm Cell Therapeutics?
Brainstorm Cell Therapeutics’s analyst rating consensus is a Hold. This is based on the ratings of 1 Wall Street analysts.
How can I buy shares of Brainstorm Cell Therapeutics?
To buy shares of DE:GHD, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.